Exicure is an early-stage biotechnology company developing nucleic acid therapies targeting ribonucleic acid against validated targets to neurological disorders and hair loss. Co. is focus on realignment of its research and development resources to support the development of its preclinical program targeting SCN9A for neuropathic pain; the development of its partnered programs to develop Spherical Nucleic Acid, or SNA-based treatments in neuroscience targeting Huntington's disease and Angelman syndrome; the development of its partnered program to develop SNA-based treatments for hair loss disorders; and the research and development of other undisclosed therapeutic product candidates. The XCUR stock yearly return is shown above.
The yearly return on the XCUR stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the XCUR annual return calculation with any dividends reinvested as applicable (on ex-dates).
|